FLT3 tyrosine kinase inhibitors (TKI) recently emerged as an efficient boost to conventional AML induction chemotherapy, significantly improving survival of FLT3 mutated AML patients in large prospective trials (2). This evidence concerns the gene FLT3 and acute myeloid leukemia.